Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) EBITDA Margin (2020 - 2025)

Apellis Pharmaceuticals has reported EBITDA Margin over the past 6 years, most recently at 29.34% for Q4 2025.

  • Quarterly results put EBITDA Margin at 29.34% for Q4 2025, down 1216.0% from a year ago — trailing twelve months through Dec 2025 was 2.35% (up 2765.0% YoY), and the annual figure for FY2025 was 2.35%, up 2765.0%.
  • EBITDA Margin for Q4 2025 was 29.34% at Apellis Pharmaceuticals, down from 47.08% in the prior quarter.
  • Over the last five years, EBITDA Margin for APLS hit a ceiling of 47.08% in Q3 2025 and a floor of 35216.69% in Q2 2021.
  • Median EBITDA Margin over the past 5 years was 127.27% (2023), compared with a mean of 2280.17%.
  • Peak annual rise in EBITDA Margin hit 3425412bps in 2022, while the deepest fall reached -47743bps in 2022.
  • Apellis Pharmaceuticals' EBITDA Margin stood at 245.5% in 2021, then tumbled by -194bps to 722.94% in 2022, then surged by 91bps to 62.2% in 2023, then skyrocketed by 72bps to 17.18% in 2024, then plummeted by -71bps to 29.34% in 2025.
  • The last three reported values for EBITDA Margin were 29.34% (Q4 2025), 47.08% (Q3 2025), and 23.34% (Q2 2025) per Business Quant data.